Australia markets closed

Bausch + Lomb Corporation (BLCO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
17.52+0.11 (+0.63%)
At close: 04:00PM EST
17.17 -0.35 (-2.00%)
After hours: 04:25PM EST

Bausch + Lomb Corporation

520 Applewood Crescent
Vaughan, ON L4K 4B4
Canada
905 695 7700
https://www.bausch.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees12,800

Key executives

NameTitlePayExercisedYear born
Mr. Joseph C. PapaCEO & Director4.08MN/A1956
Mr. Osama A. EldessoukyExec. VP & CFO1.37MN/A1972
Ms. Christina M. AckermannExec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals1.63M2.06M1965
Mr. Joseph F. GordonPres of Global Consumer, Surgical & Vision Care1.36MN/A1965
Ms. Kelly WebberExec. VP & Chief HR OfficerN/AN/AN/A
Dr. Yehia Hashad M.D.Exec. VP of R&D and Chief Medical officerN/AN/A1967
Mr. Louis W. YuExec. VP & Chief Quality OfficerN/AN/A1950
Mr. Dennis AsharinExec. VP and Chief Global Manufacturing & Supply Chain OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Corporate governance

Bausch + Lomb Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.